Results 271 to 280 of about 100,175 (352)

Diagnostic and Therapeutic Potential of Substance P/NK1 Receptor in Primary Dysmenorrhea: A Pilot Study

open access: yesHealth Science Reports, Volume 9, Issue 1, January 2026.
ABSTRACT Background and Aims Primary dysmenorrhea is a prevalent condition that causes significant menstrual pain and discomfort, impacting many women′s daily activities. The Substance P/NK1 receptor (SP/NK1R) pathway has been linked to the pain mechanisms underlying dysmenorrhea, yet its potential as a therapeutic target remains inadequately explored.
Riffat Mehboob   +8 more
wiley   +1 more source

Weight‐Reduction and Safety Profile of Once‐Weekly Non‐Comparable Biotherapeutic Subcutaneous Semaglutide Among People With Obesity: A Real‐World Retrospective Study

open access: yesHealth Science Reports, Volume 9, Issue 1, January 2026.
ABSTRACT Background and Aims Semaglutide, a once‐weekly injectable glucagon‐like peptide, showed double‐digit weight reduction with an acceptable safety profile in clinical trials and real‐world studies. The efficacy and safety of non‐comparable biotherapeutic (NCB) semaglutide are not adequately reported. Our study aimed to assess the weight reduction
Md Rakibul Hasan   +2 more
wiley   +1 more source

Fasting plasma glucose performs better than glycated hemoglobin and glycated albumin for diagnosing gestational diabetes

open access: yesInternational Journal of Gynecology &Obstetrics, Volume 172, Issue 1, Page 549-557, January 2026.
Abstract Objective Universal screening for gestational diabetes mellitus (GDM) using the oral glucose tolerance test (OGTT) has been recommended. In resource‐poor environments, OGTTs are only administered to high‐risk cases. In countries such as South Africa, where female obesity is common, this translates into high numbers of tests.
Lungile Khambule   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy